Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $25.83 Average Price Target from Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has received an average rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $25.83.

Several equities analysts have weighed in on CNTA shares. TD Cowen started coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim restated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th.

Centessa Pharmaceuticals Price Performance

CNTA opened at $16.26 on Friday. The stock has a market cap of $2.14 billion, a price-to-earnings ratio of -10.63 and a beta of 1.53. Centessa Pharmaceuticals has a 1 year low of $7.75 and a 1 year high of $19.09. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a fifty day moving average price of $16.74 and a 200 day moving average price of $15.78.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $17.66, for a total value of $176,600.00. Following the transaction, the insider now directly owns 183,266 shares in the company, valued at approximately $3,236,477.56. The trade was a 5.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Karen M. Anderson sold 30,526 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $19.03, for a total value of $580,909.78. Following the completion of the transaction, the insider now owns 54,322 shares in the company, valued at $1,033,747.66. The trade was a 35.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 397,652 shares of company stock worth $6,871,582. Company insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Harbour Capital Advisors LLC acquired a new position in Centessa Pharmaceuticals in the 3rd quarter valued at approximately $259,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after acquiring an additional 826 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Centessa Pharmaceuticals by 99.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after acquiring an additional 6,785 shares in the last quarter. Atria Investments Inc raised its holdings in Centessa Pharmaceuticals by 7.0% in the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after acquiring an additional 1,116 shares in the last quarter. Finally, GSA Capital Partners LLP raised its holdings in Centessa Pharmaceuticals by 66.1% in the 3rd quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock valued at $1,498,000 after acquiring an additional 37,275 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.